Patent ID: 11887701
Assignee: ELUCID BIOIMAGING INC.
Field: Medical technology (Instruments)
Classification: CPC G | IPC G

Claim 16:
17. A method of identifying one or more contraindications associated with an anti-inflammatory therapy for a patient diagnosed with atherosclerotic cardiovascular disease, the method comprising:
receiving a first input of non-invasively obtained imaging data related to a plaque from a set of test subjects;
receiving a second input of molecular expression data from the set of test subjects;
creating a training set comprising the first input and the second input;
training a neural network using the training set, the neural network configured to predict molecule levels based on the non-invasively obtained imaging data from the set of test subjects;
receiving non-invasively obtained imaging data related to a plaque from the patient;
generating virtual comics data that include predicted molecule levels of the patient, by applying the neural network to the non-invasively obtained imaging data from the patient;
providing the virtual comics data to a systems biology model of atherosclerotic cardiovascular disease to generate a patient-specific systems biology model, wherein
(i) the systems biology model represents a plurality of pathways associated with atherosclerotic cardiovascular disease,
(ii) each pathway in the plurality of pathways corresponds to one or more of IL-1, IL1β, TNF, IL12/23, IL17, or other cytokine molecule
(iii) the systems biology model includes a disease-associated molecule level for each molecule in the systems biology model, and
(iv) the patient-specific systems biology model includes predicted molecule levels that are updated from the disease-associated molecule level;

updating the patient-specific systems biology model with information relating to an effect on inflammation by an anti-inflammatory agent based on a known mechanism of action of the anti-inflammatory agent;
simulating a therapeutic response by the patient to the anti-inflammatory agent in the updated patient-specific systems biology model to obtain a simulated therapeutic effect, wherein the simulated therapeutic effect is based on change in the predicted molecule levels in the updated patient-specific systems biology model with and without the anti-inflammatory agent; and
identifying one or more contraindications associated with the anti-inflammatory agent based on the simulated therapeutic effect.